China Box Office: ‘Pegasus 3’ Cruises Toward $600 Million

Pegasus 3 earned RMB168.9 million ($23.8M) in the March 6–8 weekend, lifting its cumulative haul to $578.7M and putting it on track to surpass $600M. Second-place Blades of the Guardians added $11.4M (cume $180.4M) and Zhang Yimou’s Scare Out added $9.4M (cume $174.4M); Boonie Bears and Night King rounded out the top five. Mainland China weekend grosses totaled $58.2M and 2026 year-to-date box office is $1.52B, down 53.6% versus the same period in 2025, indicating a pronounced market-level slowdown despite standalone hits.

Analysis

The headline success of a single tentpole in China masks an underlying fragility: year-to-date box office is down sharply, meaning exhibitors and distributors are increasingly dependent on a handful of “event” films to carry revenue. That concentration raises earnings volatility for premium formats (IMAX, PLF) and ticketing platforms that monetize spikes — a single smash hit can drive outsized margin expansion for 4–8 weeks, but the absence of follow-through films leaves steep revenue cliffs thereafter.

Second-order winners include premium exhibition formats and ancillary sponsorship/merchandising vendors tied to big-visibility franchises: premium screen owners capture price-inelastic ticketing power and concessions margins, while advertisers and automotive partners linked to a successful racing comedy get outsized short-term ROI. Losers are the long-tail of mid-budget local films and subscription/streaming businesses that rely on steady new-release windows; a hit-driven theatrical market compresses the value of incremental library/episodic content.

Key risks and catalysts fall into two buckets. Near-term (days–weeks) box office stickiness and weekend decay rates will determine whether current tentpoles generate durable tail revenue or are front-loaded spikes; monitor second and third weekend percent declines and premium-screen sell-throughs. Over months, the pace of new approved releases and consumer discretionary health (real income, travel spending) will determine whether the market rebalances or continues to underperform versus 2025, with regulatory content approvals and piracy enforcement as wildcard catalysts.

Contrarian read: the market may be over-indexing to headline grosses and underweighting cadence risk — if calendar depth doesn’t improve, exhibitors and ticketing platforms with stretched valuations could disappoint despite headline tentpole wins. That argues for selective, event-driven exposure rather than broad long China leisure exposure.

Key Decisions for Investors

• Long IMAX (IMAX) via 3–6 month call spread or outright calls to capture premium-format upside from tentpole-driven demand. Timeframe: 3–6 months. Risk/reward: asymmetric — limited premium outlay for calls with 30–50% upside if Chinese tentpoles keep premium seat pricing and sell-through; downside ~20% if macro consumer pullback compresses admissions.
• Long Maoyan Entertainment (1896.HK) or Alibaba ticketing exposure (BABA/HK:9988) — buy 6–12 month equity to capture higher take-rates on ticket spikes and cross-sell. Timeframe: 6–12 months. Risk/reward: recurring take-rate lift during event windows can drive mid-teens revenue beats; downside if ticket volumes normalize and platform competition intensifies, use 15% stop-loss.
• Pair trade: Long IMAX (IMAX) / Short iQIYI (IQ) to express reallocation of discretionary spend from subscription/streaming to theatrical events. Timeframe: 6–12 months. Risk/reward: if theatrical cadence sustains, expect IMAX to outperform while IQ re-rates down 20–40% as SVOD ARPU comps miss; hedge sizing 1:1 dollar exposure and tighten if streaming bundling or promotions accelerate.